Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)


Volume 13, 10 Issues, 2014


Download PDF Flyer




CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 96th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Padova
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.702
5 - Year: 3.298

Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies

Author(s): S Yokobori, Mazzeo AT, S Gajavelli and Bullock MR

Affiliation: Department of Neurosurgery, University of Miami Miller School of Medicine, Lois Pope LIFE Center, Room 3-20, 1095 NW 14th Terrace, Miami, FL 33136, USA

Abstract

Traumatic brain injury (TBI) is still the worldwide, leading cause of mortality and morbidity in young adults. The prognosis of TBI patients is strongly affected by secondary brain damage including mitochondrial dysfunctions. In many basic and clinical studies, mitochondrial dysfunctions, including the opening of mitochondrial permeability transition (mPT) pore, and treatments including cyclosporine A (CsA) have been studied. These evidences suggest an important role for mitochondria as therapeutic targets for neuroprotection after TBI.

This review summarizes the data about normal and pathological mitochondrial function after TBI, TBI pathobiology relating to mitochondrial dysfunction and therapeutic strategies including drug treatment. This review also mentioned about glucose, lactate, and pyruvate metabolisms in TBI, including the "astrocyte-neuron lactate shuttle (ANLS)" hypothesis. Mitochondrial pathophysiology in TBI has still been unclear.

Thus, the pharmacological treatment in TBI patient is still challenging. Now we hope this presenting review could help further understanding of this topic. Hopefully, this could help further development and innovation for drug therapies in TBI


Keywords: Astrocyte-neuron lactate shuttle, apoptosis, cyclosporine A, mitochondrial dysfunction, mitochondrial permeability transition pore, secondary brain injury, traumatic brain injury

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 12
First Page: 1
Last Page: 14
Page Count: 14
DOI: 10.2174/18715273113126660200
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science